Targeting interleukin-2-inducible T cell kinase ameliorates immune-mediated aplastic anemia

Targeting interleukin-2-inducible T cell kinase ameliorates immune-mediated aplastic anemia

Abstract Allogeneic stem cell transplant and immunosuppressive therapy (IST) are the current standard treatments for patients with aplastic anemia (AA). However, IST also carries significant risks and side effects, and up to 30–50% of patients experienced refractory or relapsed disease following IST...

Full description

Saved in:
Bibliographic Details
Main Authors: Weiwang Li, Yu Lian, Lele Zhang, Ruonan Li, Qian Liang, Jin Mao, Chen Qiu, Haoyuan Li, Ke Huang, Qiaoli Li, Yucan Shen, Fei Yang, Linzhu Tian, Tingfang Xiao, Shilong Gu, Hong Pan, Zhen Gao, Jingyu Zhao, Liwei Fang, Meili Ge, Weiping Yuan, Yajing Chu, Jun Shi
Format: Article
Language:English
Published: Springer 2025-04-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Aplastic anemia
IL-2-induced T cell kinase
T lymphocytes
Targeted therapy
Online Access:https://doi.org/10.1007/s00262-025-04040-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-025-04040-0

Similar Items